Correction: Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease

Correction: Alz Res Therapy 17, 115 (2025)

https://doi.org/10.1186/s13195-025-01762-2

Following publication of the original article [1], an error was identified in Figure 2 of the published version. Specifically, the values displayed for the PD and OND groups in the CSF SNAP25 panel were inadvertently duplicated.

The corrected Fig. 2 is provided below.

Fig. 2.

CSF and plasma SNAP25 and VAMP2 across diagnostic groups. Panels show levels of (A) CSF SNAP25, (B) plasma SNAP25 (C) CSF VAMP2, and (D) plasma VAMP2 in AD (n = 80), PD (n = 47) and OND (n = 42). *** p < 0.001. AD: Alzheimer’s disease. CSF: cerebrospinal fluid. OND: other neurological diseases. PD: Parkinson’s disease. SNAP-25: synaptosomal-associated protein 25 kDa. VAMP2: vesicle-associated membrane protein 2

The original version of Fig. 2:

Fig. 2.

CSF and plasma SNAP25 and VAMP2 across diagnostic groups. Panels show levels of (A) CSF SNAP25, (B) plasma SNAP25 (C) CSF VAMP2, and (D) plasma VAMP2 in AD (n = 80), PD (n = 47) and OND (n = 42). *** p < 0.001. AD: Alzheimer’s disease. CSF: cerebrospinal fluid. OND: other neurological diseases. PD: Parkinson’s disease. SNAP-25: synaptosomal-associated protein 25 kDa. VAMP2: vesicle-associated membrane protein 2

The original article [1] has been updated.